Published in J Korean Med Sci on January 28, 2009
End stage and chronic kidney disease: associations with renal cancer. Front Oncol (2012) 0.98
Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World J Urol (2014) 0.92
Sex differences in the development of malignancies among end-stage renal disease patients: a nationwide population-based follow-up study in Taiwan. PLoS One (2012) 0.88
Type 1 and type 2 diabetes and cancer mortality in the 2002-2009 cohort of 39,811 French dialyzed patients. PLoS One (2015) 0.78
Death Does Matter-Cancer Risk in Patients With End-Stage Renal Disease: A Nationwide Population-Based Study With Competing Risk Analyses. Medicine (Baltimore) (2016) 0.75
Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer (2017) 0.75
Multiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient. BMJ Case Rep (2013) 0.75
Malignant tumors in patients with end stage renal failure undergoing renal replacement therapy. Contemp Oncol (Pozn) (2012) 0.75
Cancer in Korean patients with end-stage renal disease: A 7-year follow-up. PLoS One (2017) 0.75
Cancer after kidney transplantation in the United States. Am J Transplant (2004) 5.08
Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet (1999) 4.04
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int (2000) 2.72
Increased incidence of malignancy during chronic renal failure. Lancet (1975) 1.79
Cancer in patients receiving dialysis. Br Med J (1980) 1.52
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev (1996) 1.36
Cancer in end-stage renal disease: potential factors involved -editorial-. Am J Nephrol (1998) 1.28
Cancer and patients with end-stage renal failure. Br Med J (Clin Res Ed) (1982) 1.26
Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc (1985) 1.14
Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients. Nephron (1991) 1.08
[Ten year trend of cancer incidence in Seoul, Korea: 1993--2002]. J Prev Med Public Health (2008) 1.04
Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl (1994) 1.01
Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int (2004) 0.98
Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis (1993) 0.97
Are malignancies increased in uremia? Nephron (1979) 0.94
The immune status of the uremic patient: hemodialysis vs CAPD. Clin Nephrol (1988) 0.93
Cancer incidence in patients on chronic dialysis and in renal transplant recipients. Urol Int (1990) 0.92
Malignancies after renal transplantation: the EDTA-ERA registry experience. European Dialysis and Transplantation Association-European Renal Association. Nephrol Dial Transplant (1995) 0.88
Malignant tumors in hemodialysis patients. Nephron (1996) 0.86
Increased risk of malignancy and blood-membrane interactions in uraemic patients. Nephrol Dial Transplant (1994) 0.85
Effects of selenium supplementation on immune parameters in chronic uraemic patients on haemodialysis. Nephrol Dial Transplant (1995) 0.83
Cancer in uremic patients. Clin Nephrol (1984) 0.82
Development of malignancy in the end-stage renal disease patient. Semin Nephrol (1993) 0.82
Sister chromatid exchange and chromosome abnormalities in uremic patients. Cancer Genet Cytogenet (1988) 0.82
Malignant tumours in dialysis patients: a nationwide survey. Proc Eur Dial Transplant Assoc (1981) 0.81
Secondary hyperparathyroidism: evidence for an association with papillary thyroid cancer. Am Surg (2001) 0.81
Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant (1994) 0.80
Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int Suppl (1994) 0.79
Carcinogenic glutamic acid pyrolysis product in the dialysate of uremic patients treated by continuous ambulatory peritoneal dialysis. Clin Nephrol (1988) 0.78
Renal cell carcinoma in chronic hemodialysis patients--a 1990 questionnaire study in Japan. Kidney Int Suppl (1993) 0.78
[Cancer of the bladder and hemodialysis]. Arch Esp Urol (1990) 0.77
Multiple complications in multiple myeloma. Am J Kidney Dis (2005) 0.77
Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int (2005) 3.03
Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. Perit Dial Int (2004) 2.13
Intratympanic steroid injection for Bell's palsy: preliminary randomized controlled study. Otol Neurotol (2014) 2.00
Improving outcome of CAPD: twenty-five years' experience in a single Korean center. Perit Dial Int (2007) 1.83
Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer. Ann Thorac Surg (2011) 1.80
Circulating α-klotho levels in CKD and relationship to progression. Am J Kidney Dis (2013) 1.76
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.63
Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant (2006) 1.63
Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant (2008) 1.55
Risk factors for adverse outcomes after peritonitis-related technique failure. Perit Dial Int (2008) 1.54
Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transplant (2009) 1.53
Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer. Thyroid (2013) 1.52
Association of inflammation and protein-energy wasting with endothelial dysfunction in peritoneal dialysis patients. Nephrol Dial Transplant (2009) 1.50
Production of branched-chain alkylprodiginines in S. coelicolor by replacement of the 3-ketoacyl ACP synthase III initiation enzyme, RedP. Chem Biol (2005) 1.50
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer (2011) 1.49
Identification of HnRNP-A2/B1 as a target antigen of anti-endothelial cell IgA antibody in Behçet's disease. J Invest Dermatol (2011) 1.46
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Support Care Cancer (2013) 1.42
Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches. Transpl Int (2012) 1.40
High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res (2012) 1.39
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One (2013) 1.37
Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Nephrol Dial Transplant (2011) 1.34
The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int (2008) 1.34
Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: multi-center experience in Korea. Yonsei Med J (2005) 1.32
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med (2011) 1.26
New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol (2010) 1.25
Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol (2012) 1.21
Retracted Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J (2012) 1.20
Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant (2007) 1.19
Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J (2012) 1.16
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther (2012) 1.16
Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis (2011) 1.16
An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock. Crit Care (2013) 1.14
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res (2006) 1.12
Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients. Nephrol Dial Transplant (2009) 1.11
Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis (2009) 1.11
Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol (2009) 1.11
Enhancement and selective production of phoslactomycin B, a protein phosphatase IIa inhibitor, through identification and engineering of the corresponding biosynthetic gene cluster. J Biol Chem (2003) 1.10
Generation of multiple bioactive macrolides by hybrid modular polyketide synthases in Streptomyces venezuelae. Chem Biol (2002) 1.10
High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res (2009) 1.10
Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. J Biol Chem (2012) 1.09
Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol (2004) 1.08
Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One (2012) 1.08
Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol (2002) 1.07
Cloning, sequencing, and characterization of the pradimicin biosynthetic gene cluster of Actinomadura hibisca P157-2. J Microbiol Biotechnol (2007) 1.07